Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Review

Glycogen synthase kinase 3 beta: can it be a target for oral cancer

Author: Rajakishore Mishra

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Despite progress in treatment approaches for oral cancer, there has been only modest improvement in patient outcomes in the past three decades. The frequent treatment failure is due to the failure to control tumor recurrence and metastasis. These failures suggest that new targets should be identified to reverse oral epithelial dysplastic lesions. Recent developments suggest an active role of glycogen synthase kinase 3 beta (GSK3 β) in various human cancers either as a tumor suppressor or as a tumor promoter. GSK3β is a Ser/Thr protein kinase, and there is emerging evidence that it is a tumor suppressor in oral cancer. The evidence suggests a link between key players in oral cancer that control transcription, accelerated cell cycle progression, activation of invasion/metastasis and anti-apoptosis, and regulation of these factors by GSK3β. Moreover, the major upstream kinases of GSK3β and their oncogenic activation by several etiological agents of oral cancer support this hypothesis. In spite of all this evidence, a detailed analysis of the role of GSK3β in oral cancer and of its therapeutic potential has yet to be conducted by the scientific community. The focus of this review is to discuss the multitude of roles of GSK3β, its possible role in controlling different oncogenic events and how it can be targeted in oral cancer.
Appendix
Available only for authorised users
Literature
1.
Cheong SC, Chandramouli GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathan R, Prime SS, Teo SH, Patel V, Gutkind JS: Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol. 2009, 45: 712-719. 10.1016/j.oraloncology.2008.11.002PubMedCrossRef
2.
Mishra A, Bharti AC, Saluja D, Das BC: Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer. 2010, 126: 819-829.PubMed
3.
Scully C, Bagan JV: Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol. 2009, 45: e25-30. 10.1016/j.oraloncology.2008.12.011PubMedCrossRef
4.
zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009, 384: 260-265. 10.1016/j.virol.2008.11.046PubMedCrossRef
5.
Paterson IC, Eveson JW, Prime SS: Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol. 1996, 32B: 150-153. 10.1016/0964-1955(95)00065-8PubMedCrossRef
6.
Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck. 2008, 30: 800-809. 10.1002/hed.20830PubMedCrossRef
7.
Kim M, Datta A, Brakeman P, Yu W, Mostov KE: Polarity proteins PAR6 and aPKC regulate cell death through GSK-3beta in 3D epithelial morphogenesis. J Cell Sci. 2007, 120: 2309-2317. 10.1242/jcs.007443PubMedCrossRef
8.
9.
Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB: Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA. 2000, 97: 11960-11965. 10.1073/pnas.220413597PubMedCentralPubMedCrossRef
10.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995, 378: 785-789. 10.1038/378785a0PubMedCrossRef
11.
Kim MJ, Lee JH, Kim YK, Myoung H, Yun PY: The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines. Cancer Lett. 2007, 245: 284-292. 10.1016/j.canlet.2006.01.017PubMedCrossRef
12.
Stambolic V, Woodgett JR: Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J. 1994, 303 (Pt 3): 701-704.PubMedCentralPubMedCrossRef
13.
Sutherland C, Leighton IA, Cohen P: Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J. 1993, 296 (Pt 1): 15-19.PubMedCentralPubMedCrossRef
14.
Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI, Hong SP: Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol. 2005, 58: 1199-1205. 10.1136/jcp.2004.024786PubMedCentralPubMedCrossRef
15.
Wu HT, Ko SY, Fong JH, Chang KW, Liu TY, Kao SY: Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. J Oral Pathol Med. 2009, 38: 206-213.PubMedCrossRef
16.
Iamaroon A, Krisanaprakornkit S: Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 2009, 45: e175-179. 10.1016/j.oraloncology.2009.06.003PubMedCrossRef
17.
Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980, 107: 519-527.PubMedCrossRef
18.
19.
20.
Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009, 273: 194-200. 10.1016/j.canlet.2008.05.045PubMedCrossRef
21.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science. 2002, 298: 1912-1934. 10.1126/science.1075762PubMedCrossRef
22.
Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002, 2: 740-749. 10.1038/nrc906PubMedCrossRef
23.
Tsai WC, Tsai ST, Ko JY, Jin YT, Li C, Huang W, Young KC, Lai MD, Liu HS, Wu LW: The mRNA profile of genes in betel quid chewing oral cancer patients. Oral Oncol. 2004, 40: 418-426. 10.1016/j.oraloncology.2003.09.015PubMedCrossRef
24.
de Groot RP, Auwerx J, Bourouis M, Sassone-Corsi P: Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene. 1993, 8: 841-847.PubMed
25.
Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M: Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem. 2004, 279: 49571-49574. 10.1074/jbc.C400442200PubMedCrossRef
26.
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004, 23: 2116-2125. 10.1038/sj.emboj.7600217PubMedCentralPubMedCrossRef
27.
Ciani L, Salinas PC: WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005, 6: 351-362. 10.1038/nrn1665PubMedCrossRef
28.
Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J: A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006, 8: 1398-1406. 10.1038/ncb1508PubMedCrossRef
29.
GA M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A: Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002, 297: 760-764. 10.1016/S0006-291X(02)02278-7CrossRef
30.
Ross SE, Erickson RL, Hemati N, MacDougald OA: Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol. 1999, 19: 8433-8441.PubMedCentralPubMedCrossRef
31.
Gotschel F, Kern C, Lang S, Sparna T, Markmann C, Schwager J, McNelly S, von Weizsacker F, Laufer S, Hecht A, Merfort I: Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp Cell Res. 2008, 314: 1351-1366. 10.1016/j.yexcr.2007.12.015PubMedCrossRef
32.
de Sousa SO, Mesquita RA, Pinto DS, Gutkind S: Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J Oral Pathol Med. 2002, 31: 78-81.PubMedCrossRef
33.
Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR: Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991, 353: 670-674. 10.1038/353670a0PubMedCrossRef
34.
Chen RH, Juo PC, Curran T, Blenis J: Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene. 1996, 12: 1493-1502.PubMed
35.
Mishra A, Bharti AC, Varghese P, Saluja D, Das BC: Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer. 2006, 119: 2840-2850. 10.1002/ijc.22262PubMedCrossRef
36.
Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, Ohmori H, Luo Y, Yasui W, Bosserhoff AK, Kuniyasu H: High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci. 2008, 99: 1806-1812.PubMed
37.
Ma Y, Wang M, Li N, Wu R, Wang X: Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta. Toxicol Lett. 2009, 187: 194-200. 10.1016/j.toxlet.2009.02.023PubMedCrossRef
38.
Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S, Maggirwar SB: Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol. 2003, 23: 4649-4662. 10.1128/MCB.23.13.4649-4662.2003PubMedCentralPubMedCrossRef
39.
Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol. 2005, 168: 29-33. 10.1083/jcb.200409067PubMedCentralPubMedCrossRef
40.
Tian D, Zhu M, Chen WS, Li JS, Wu RL, Wang X: Role of glycogen synthase kinase 3 in squamous differentiation induced by cigarette smoke in porcine tracheobronchial epithelial cells. Food Chem Toxicol. 2006, 44: 1590-1596. 10.1016/j.fct.2006.03.013PubMedCrossRef
41.
Vora HH, Shah NG, Trivedi TI, Goswami JV, Shukla SN, Shah PM: Expression of C-Myc mRNA in squamous cell carcinoma of the tongue. J Surg Oncol. 2007, 95: 70-78. 10.1002/jso.20675PubMedCrossRef
42.
Baral R, Patnaik S, Das BR: Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci. 1998, 106: 907-913. 10.1046/j.0909-8836.1998.eos106502.xPubMedCrossRef
43.
Mahomed F, Altini M, Meer S: Altered E-cadherin/beta-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis. 2007, 13: 386-392. 10.1111/j.1601-0825.2006.01295.xPubMedCrossRef
44.
Tanaka N, Odajima T, Ogi K, Ikeda T, Satoh M: Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer. 2003, 89: 557-563. 10.1038/sj.bjc.6601124PubMedCentralPubMedCrossRef
45.
Bankfalvi A, Krassort M, Vegh A, Felszeghy E, Piffko J: Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med. 2002, 31: 450-457. 10.1034/j.1600-0714.2002.00147.xPubMedCrossRef
46.
de Castro J, Gamallo C, Palacios J, Moreno-Bueno G, Rodriguez N, Feliu J, Gonzalez-Baron M: beta-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Arch. 2000, 437: 599-604. 10.1007/s004280000266PubMedCrossRef
47.
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG: c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000, 95: 2104-2110.PubMed
48.
Oster SK, Ho CS, Soucie EL, Penn LZ: The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002, 84: 81-154. full_textPubMedCrossRef
49.
Gregory MA, Qi Y, Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003, 278: 51606-51612. 10.1074/jbc.M310722200PubMedCrossRef
50.
An J, Yang DY, Xu QZ, Zhang SM, Huo YY, Shang ZF, Wang Y, Wu DC, Zhou PK: DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. Mol Cancer. 2008, 7: 32- 10.1186/1476-4598-7-32PubMedCentralPubMedCrossRef
51.
Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, Sasaki Y, Hiratsuka H, Tokino T: Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol. 2008, 32: 1253-1261.PubMed
52.
Iwai S, Katagiri W, Kong C, Amekawa S, Nakazawa M, Yura Y: Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005, 131: 773-782. 10.1007/s00432-005-0027-yPubMedCrossRef
53.
Yeh KT, Chang JG, Lin TH, Wang YF, Chang JY, Shih MC, Lin CC: Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. Int J Oncol. 2003, 23: 1001-1007.PubMed
54.
Franz M, Spiegel K, Umbreit C, Richter P, Codina-Canet C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kosmehl H, Virtanen I: Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol. 2009, 131: 651-660. 10.1007/s00418-009-0559-3PubMedCrossRef
55.
Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004, 6: 931-940. 10.1038/ncb1173PubMedCrossRef
56.
Doble BW, Woodgett JR: Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs. 2007, 185: 73-84. 10.1159/000101306PubMedCrossRef
57.
Oren M: Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10: 431-442. 10.1038/sj.cdd.4401183PubMedCrossRef
58.
Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem. 2003, 278: 48872-48879. 10.1074/jbc.M305870200PubMedCentralPubMedCrossRef
59.
60.
Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z, Luo J: The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res. 2007, 67: 7756-7764. 10.1158/0008-5472.CAN-06-4665PubMedCrossRef
61.
Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R: Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 2003, 63: 4796-4800.PubMed
62.
Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res. 2004, 10: 4029-4037. 10.1158/1078-0432.CCR-03-0249PubMedCrossRef
63.
Suzuki M, Shinohara F, Endo M, Sugazaki M, Echigo S, Rikiishi H: Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2009, 64: 223-232. 10.1007/s00280-008-0833-4PubMedCrossRef
64.
Bauer K, Dowejko A, Bosserhoff AK, Reichert TE, Bauer RJ: P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated Snail phosphorylation. Carcinogenesis. 2009, 30: 1781-1788. 10.1093/carcin/bgp175PubMedCrossRef
65.
Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009, 9: 153-166. 10.1038/nrc2602PubMedCrossRef
66.
Sartor M, Steingrimsdottir H, Elamin F, Gaken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M: Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer. 1999, 80: 79-86. 10.1038/sj.bjc.6690505PubMedCentralPubMedCrossRef
67.
Turatti E, da Costa Neves A, de Magalhaes MH, de Sousa SO: Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci. 2005, 47: 71-76. 10.2334/josnusd.47.71PubMedCrossRef
68.
Mihara M, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, Wong DT: Overexpression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res. 2001, 92: 352-360.PubMedCrossRef
69.
Fraczek M, Wozniak Z, Ramsey D, Krecicki T: Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis. Eur Arch Otorhinolaryngol. 2007, 264: 923-928. 10.1007/s00405-007-0276-2PubMedCrossRef
70.
Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12: 3499-3511. 10.1101/gad.12.22.3499PubMedCentralPubMedCrossRef
71.
Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE, Roberts JM: Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 2003, 12: 381-392. 10.1016/S1097-2765(03)00287-9PubMedCrossRef
72.
Leis H, Segrelles C, Ruiz S, Santos M, Paramio JM: Expression, localization, and activity of glycogen synthase kinase 3beta during mouse skin tumorigenesis. Mol Carcinog. 2002, 35: 180-185. 10.1002/mc.10087PubMedCrossRef
73.
Goto H, Kawano K, Kobayashi I, Sakai H, Yanagisawa S: Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol. 2002, 38: 549-556. 10.1016/S1368-8375(01)00121-XPubMedCrossRef
74.
Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D: Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004, 64: 5982-5987. 10.1158/0008-5472.CAN-04-0993PubMedCrossRef
75.
Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, Sugano I, Ishida Y: Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus. J Clin Pathol. 2005, 58: 904-910. 10.1136/jcp.2004.023127PubMedCentralPubMedCrossRef
76.
Meyer N, Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer. 2008, 8: 976-990. 10.1038/nrc2231PubMedCrossRef
77.
Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML: Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol. 2004, 24: 7538-7547. 10.1128/MCB.24.17.7538-7547.2004PubMedCentralPubMedCrossRef
78.
Nadal A, Jares P, Pinyol M, Conde L, Romeu C, Fernandez PL, Campo E, Cardesa A: Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. Virchows Arch. 2007, 450: 161-167. 10.1007/s00428-006-0314-2PubMedCrossRef
79.
Nemes JA, Nemes Z, Marton IJ: p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2005, 34: 274-279. 10.1111/j.1600-0714.2005.00310.xPubMedCrossRef
80.
Yokoyama K, Kamata N, Fujimoto R, Tsutsumi S, Tomonari M, Taki M, Hosokawa H, Nagayama M: Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int J Oncol. 2003, 22: 891-898.PubMed
81.
Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S: Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem. 2002, 277: 9684-9689. 10.1074/jbc.M106157200PubMedCrossRef
82.
Kudo Y, Kitajima S, Ogawa I, Miyauchi M, Takata T: Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma. Oral Oncol. 2005, 41: 105-116. 10.1016/j.oraloncology.2004.05.003PubMedCrossRef
83.
Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, Wickrema A: Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma. 2008, 49: 1945-1953. 10.1080/10428190802304966PubMedCentralPubMedCrossRef
84.
Reagan-Shaw S, Ahmad N: RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res. 2006, 66: 1062-1069. 10.1158/0008-5472.CAN-05-1018PubMedCrossRef
85.
Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R, Tao Q: The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res. 2005, 11: 6442-6449. 10.1158/1078-0432.CCR-05-0267PubMedCrossRef
86.
Chen JC, Lu KW, Tsai ML, Hsu SC, Kuo CL, Yang JS, Hsia TC, Yu CS, Chou ST, Kao MC: Gypenosides induced G0/G1 arrest via CHk2 and apoptosis through endoplasmic reticulum stress and mitochondria-dependent pathways in human tongue cancer SCC-4 cells. Oral Oncol. 2009, 45: 273-283. 10.1016/j.oraloncology.2008.05.012PubMedCrossRef
87.
Obaya AJ, Mateyak MK, Sedivy JM: Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene. 1999, 18: 2934-2941. 10.1038/sj.onc.1202749PubMedCrossRef
88.
Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H: GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell. 2008, 13: 36-47. 10.1016/j.ccr.2007.12.002PubMedCentralPubMedCrossRef
89.
Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF: Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002, 161: 1881-1891.PubMedCentralPubMedCrossRef
90.
Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, Teng SC, Wu KJ: Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene. 2007, 26: 1459-1467. 10.1038/sj.onc.1209929PubMedCrossRef
91.
Kosmehl H, Berndt A, Strassburger S, Borsi L, Rousselle P, Mandel U, Hyckel P, Zardi L, Katenkamp D: Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer. 1999, 81: 1071-1079. 10.1038/sj.bjc.6690809PubMedCentralPubMedCrossRef
92.
Mhawech P, Dulguerov P, Assaly M, Ares C, Allal AS: EB-D fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncol. 2005, 41: 82-88. 10.1016/j.oraloncology.2004.07.003PubMedCrossRef
93.
de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C: Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. Oncogene. 2007, 26: 382-394. 10.1038/sj.onc.1209804PubMedCrossRef
94.
Haraguchi M, Okubo T, Miyashita Y, Miyamoto Y, Hayashi M, Crotti TN, McHugh KP, Ozawa M: Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins. J Biol Chem. 2008, 283: 23514-23523. 10.1074/jbc.M801125200PubMedCentralPubMedCrossRef
95.
Erdem NF, Carlson ER, Gerard DA, Ichiki AT: Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg. 2007, 65: 1725-1733. 10.1016/j.joms.2006.11.034PubMedCrossRef
96.
Ziober BL, Silverman SS, Kramer RH: Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med. 2001, 12: 499-510. 10.1177/10454411010120060401PubMedCrossRef
97.
Kornberg LJ: Focal adhesion kinase expression in oral cancers. Head Neck. 1998, 20: 634-639. 10.1002/(SICI)1097-0347(199810)20:7<634::AID-HED10>3.0.CO;2-MPubMedCrossRef
98.
Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC: Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci. 2010, 86: 199-206. 10.1016/j.lfs.2009.12.003PubMedCrossRef
99.
Bianchi M, De Lucchini S, Marin O, Turner DL, Hanks SK, Villa-Moruzzi E: Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochem J. 2005, 391: 359-370. 10.1042/BJ20050282PubMedCentralPubMedCrossRef
100.
Ramos DM, Dang D, Sadler S: The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res. 2009, 29: 125-130.PubMed
101.
Han S, Roman J: COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites. Int J Cancer. 2005, 116: 536-546. 10.1002/ijc.21125PubMedCrossRef
102.
Zutter MM, Santoro SA, Painter AS, Tsung YL, Gafford A: The human alpha 2 integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression. J Biol Chem. 1994, 269: 463-469.PubMed
103.
Nishida K, Kitazawa R, Mizuno K, Maeda S, Kitazawa S: Identification of regulatory elements of human alpha 6 integrin subunit gene. Biochem Biophys Res Commun. 1997, 241: 258-263. 10.1006/bbrc.1997.7808PubMedCrossRef
104.
Corbi AL, Jensen UB, Watt FM: The alpha2 and alpha5 integrin genes: identification of transcription factors that regulate promoter activity in epidermal keratinocytes. FEBS Lett. 2000, 474: 201-207. 10.1016/S0014-5793(00)01591-XPubMedCrossRef
105.
Barrallo-Gimeno A, Nieto MA: The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005, 132: 3151-3161. 10.1242/dev.01907PubMedCrossRef
106.
Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DT, Schmidt BL: Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res. 2004, 10: 6460-6465. 10.1158/1078-0432.CCR-04-0656PubMedCrossRef
107.
Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004, 10: 634-640. 10.1158/1078-0432.CCR-0864-02PubMedCrossRef
108.
Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T: Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer. 1998, 77: 2239-2245.PubMedCentralPubMedCrossRef
109.
Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, Isaka K, Saarialho-Kere U: Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol. 2004, 202: 14-22. 10.1002/path.1479PubMedCrossRef
110.
Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis. 2004, 21: 737-745. 10.1007/s10585-005-1190-xPubMedCrossRef
111.
Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, Sironen R, Juhola M, Kumpulainen E, Johansson R: CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol. 2007, 43: 51-59. 10.1016/j.oraloncology.2006.01.003PubMedCrossRef
112.
Lee CH, Liu SY, Lin MH, Chiang WF, Chen TC, Huang WT, Chou DS, Chiu CT, Liu YC: Upregulation of matrix metalloproteinase-1 (MMP-1) expression in oral carcinomas of betel quid (BQ) users: roles of BQ ingredients in the acceleration of tumour cell motility through MMP-1. Arch Oral Biol. 2008, 53: 810-818. 10.1016/j.archoralbio.2008.05.004PubMedCrossRef
113.
Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, Nagayama M: Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 2001, 37: 65-71. 10.1016/S1368-8375(00)00059-2PubMedCrossRef
114.
Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M: Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. 2003, 94: 593-597. 10.1111/j.1349-7006.2003.tb01488.xPubMedCrossRef
115.
Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 1991, 51: 6328-6337.PubMed
116.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2: 84-89. 10.1038/35000034PubMedCrossRef
117.
Sappayatosok K, Maneerat Y, Swasdison S, Viriyavejakul P, Dhanuthai K, Zwang J, Chaisri U: Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal. 2009, 14: E319-324.PubMed
118.
Nystrom ML, McCulloch D, Weinreb PH, Violette SM, Speight PM, Marshall JF, Hart IR, Thomas GJ: Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 2006, 66: 10833-10842. 10.1158/0008-5472.CAN-06-1640PubMedCrossRef
119.
Kurihara Y, Hatori M, Ando Y, Ito D, Toyoshima T, Tanaka M, Shintani S: Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis. 2009, 26: 425-432. 10.1007/s10585-009-9241-3PubMedCrossRef
120.
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999, 274: 10911-10915. 10.1074/jbc.274.16.10911PubMedCrossRef
121.
Chiang SL, Chen PH, Lee CH, Ko AM, Lee KW, Lin YC, Ho PS, Tu HP, Wu DC, Shieh TY, Ko YC: Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G > a polymorphism reveal risk of oral cancer. Cancer Res. 2008, 68: 8489-8498. 10.1158/0008-5472.CAN-08-0823PubMedCrossRef
122.
Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M: Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer. 2004, 108: 912-921. 10.1002/ijc.11640PubMedCrossRef
123.
Beurel E, Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006, 79: 173-189. 10.1016/j.pneurobio.2006.07.006PubMedCentralPubMedCrossRef
124.
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000, 406: 86-90. 10.1038/35017574PubMedCrossRef
125.
Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q: Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 2005, 65: 9012-9020. 10.1158/0008-5472.CAN-05-1226PubMedCrossRef
126.
Lonze BE, Ginty DD: Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002, 35: 605-623. 10.1016/S0896-6273(02)00828-0PubMedCrossRef
127.
Uchida M, Iwase M, Takaoka S, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M, Shintani S: Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. Int J Oncol. 2007, 30: 1163-1171.PubMed
128.
Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W: t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res. 2008, 68: 395-403. 10.1158/0008-5472.CAN-07-1580PubMedCrossRef
129.
Ballou LM, Tian PY, Lin HY, Jiang YP, Lin RZ: Dual regulation of glycogen synthase kinase-3beta by the alpha1A-adrenergic receptor. J Biol Chem. 2001, 276: 40910-40916. 10.1074/jbc.M103480200PubMedCrossRef
130.
Tanji C, Yamamoto H, Yorioka N, Kohno N, Kikuchi K, Kikuchi A: A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. J Biol Chem. 2002, 277: 36955-36961. 10.1074/jbc.M206210200PubMedCrossRef
131.
Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C: Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res. 2009, 15: 5974-5984. 10.1158/1078-0432.CCR-09-1352PubMedCentralPubMedCrossRef
132.
Tosi L, Rinaldi E, Carinci F, Farina A, Pastore A, Pelucchi S, Cassano L, Evangelisti R, Carinci P, Volinia S: Akt, protein kinase C, and mitogen-activated protein kinase phosphorylation status in head and neck squamous cell carcinoma. Head Neck. 2005, 27: 130-137. 10.1002/hed.20120PubMedCrossRef
133.
Moral M, Paramio JM: Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol. 2008, 23: 1269-1278.PubMed
134.
Tsai CH, Hsieh YS, Yang SF, Chou MY, Chang YC: Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003, 95: 710-716. 10.1067/moe.2003.121PubMedCrossRef
135.
Pan Q, Bao LW, Teknos TN, Merajver SD: Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 2006, 66: 9379-9384. 10.1158/0008-5472.CAN-06-2646PubMedCentralPubMedCrossRef
136.
Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR: RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell. 2009, 35: 511-522. 10.1016/j.molcel.2009.08.002PubMedCentralPubMedCrossRef
137.
Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF: Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009, 69: 2568-2576. 10.1158/0008-5472.CAN-08-3199PubMedCrossRef
138.
Saito Y, Vandenheede JR, Cohen P: The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J. 1994, 303 (Pt 1): 27-31.PubMedCentralPubMedCrossRef
139.
Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS: Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005, 65: 9953-9961. 10.1158/0008-5472.CAN-05-0921PubMedCrossRef
140.
West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA: Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003, 111: 81-90.PubMedCentralPubMedCrossRef
141.
Hope BT, Nagarkar D, Leonard S, Wise RA: Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. J Neurosci. 2007, 27: 1964-1972. 10.1523/JNEUROSCI.3661-06.2007PubMedCentralPubMedCrossRef
142.
Du B, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ: Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res. 2005, 65: 5982-5988. 10.1158/0008-5472.CAN-05-0628PubMedCrossRef
143.
Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002, 3: 461-469. 10.1016/S1470-2045(02)00815-XPubMedCrossRef
144.
Nakayama H, Numakawa T, Ikeuchi T: Nicotine-induced phosphorylation of Akt through epidermal growth factor receptor and Src in PC12h cells. J Neurochem. 2002, 83: 1372-1379. 10.1046/j.1471-4159.2002.01248.xPubMedCrossRef
145.
Sugano N, Minegishi T, Kawamoto K, Ito K: Nicotine inhibits UV-induced activation of the apoptotic pathway. Toxicol Lett. 2001, 125: 61-65. 10.1016/S0378-4274(01)00416-7PubMedCrossRef
146.
Etique N, Flament S, Lecomte J, Grillier-Vuissoz I: Ethanol-induced ligand-independent activation of ERalpha mediated by cyclic AMP/PKA signaling pathway: an in vitro study on MCF-7 breast cancer cells. Int J Oncol. 2007, 31: 1509-1518.PubMed
147.
Pim D, Massimi P, Dilworth SM, Banks L: Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene. 2005, 24: 7830-7838. 10.1038/sj.onc.1208935PubMedCrossRef
148.
Perez-Plasencia C, Vazquez-Ortiz G, Lopez-Romero R, Pina-Sanchez P, Moreno J, Salcedo M: Genome wide expression analysis in HPV16 Cervical Cancer: identification of altered metabolic pathways. Infect Agent Cancer. 2007, 2: 16- 10.1186/1750-9378-2-16PubMedCentralPubMedCrossRef
149.
Sun Y: p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog. 2006, 45: 409-415. 10.1002/mc.20231PubMedCrossRef
150.
Matsuda T, Zhai P, Maejima Y, Hong C, Gao S, Tian B, Goto K, Takagi H, Tamamori-Adachi M, Kitajima S, Sadoshima J: Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci USA. 2008, 105: 20900-20905. 10.1073/pnas.0808315106PubMedCentralPubMedCrossRef
151.
Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D: Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol. 2002, 9: 940-944. 10.1038/nsb870PubMedCrossRef
152.
Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH: Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 2003, 22: 494-501. 10.1093/emboj/cdg068PubMedCentralPubMedCrossRef
153.
Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ: The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure. 2001, 9: 1143-1152. 10.1016/S0969-2126(01)00679-7PubMedCrossRef
154.
Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 2001, 105: 721-732. 10.1016/S0092-8674(01)00374-9PubMedCrossRef
155.
Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998, 16: 2221-2232.PubMed
156.
Cao Q, Lu X, Feng YJ: Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 2006, 16: 671-677. 10.1038/sj.cr.7310078PubMedCrossRef
157.
Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B: Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate. 2007, 67: 976-988. 10.1002/pros.20586PubMedCrossRef
158.
Ghosh JC, Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res. 2005, 11: 4580-4588. 10.1158/1078-0432.CCR-04-2624PubMedCrossRef
159.
Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, Kawakami K, Minamoto T: Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 2007, 98: 1388-1393. 10.1111/j.1349-7006.2007.00545.xPubMedCrossRef
160.
161.
Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD: Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006, 12: 5074-5081. 10.1158/1078-0432.CCR-06-0196PubMedCentralPubMedCrossRef
162.
Garcea G, Manson MM, Neal CP, Pattenden CJ, Sutton CD, Dennison AR, Berry DP: Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?. Curr Cancer Drug Targets. 2007, 7: 209-215. 10.2174/156800907780618266PubMedCrossRef
163.
Mamaghani S, Patel S, Hedley DW: Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009, 9: 132- 10.1186/1471-2407-9-132PubMedCentralPubMedCrossRef
164.
Zhou H, Tang Y, Liang X, Yang X, Yang J, Zhu G, Zheng M, Zhang C: RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int J Cancer. 2009, 125: 453-462. 10.1002/ijc.24360PubMedCrossRef
165.
Lage H: Therapeutic potential of RNA interference in drug-resistant cancers. Future Oncol. 2009, 5: 169-185. 10.2217/14796694.5.2.169PubMedCrossRef
166.
Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y, Minamoto T: Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res. 2009, 15: 6810-6819. 10.1158/1078-0432.CCR-09-0973PubMedCrossRef
167.
Weinstein IB: Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002, 297: 63-64. 10.1126/science.1073096PubMedCrossRef
168.
Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, Lee DF, Yang JY, Xie X, Liu JC, Hung MC: Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007, 67: 4564-4571. 10.1158/0008-5472.CAN-06-1788PubMedCrossRef
169.
Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD, Seldin DC: Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 2005, 65: 5792-5801. 10.1158/0008-5472.CAN-05-1021PubMedCrossRef
170.
Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005, 65: 1961-1972. 10.1158/0008-5472.CAN-04-2501PubMedCrossRef
171.
Dal Col J, Dolcetti R: GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle. 2008, 7: 2813-2816.PubMedCrossRef
172.
Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A: Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006, 66: 11462-11470. 10.1158/0008-5472.CAN-06-1969PubMedCrossRef
173.
Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N: Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 2004, 64: 5251-5260. 10.1158/0008-5472.CAN-04-0538PubMedCrossRef
174.
Zheng H, Saito H, Masuda S, Yang X, Takano Y: Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res. 2007, 27: 3561-3569.PubMed
175.
Mai W, Miyashita K, Shakoori A, Zhang B, Yu ZW, Takahashi Y, Motoo Y, Kawakami K, Minamoto T: Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay. Oncology. 2006, 71: 297-305. 10.1159/000106429PubMedCrossRef
176.
Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD: Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65: 2076-2081. 10.1158/0008-5472.CAN-04-3642PubMedCrossRef
177.
Ougolkov AV, Billadeau DD: Targeting GSK-3: a promising approach for cancer therapy?. Future Oncol. 2006, 2: 91-100. 10.2217/14796694.2.1.91PubMedCrossRef
178.
Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T, Tomita Y: Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer. 2009, 101: 2005-2014. 10.1038/sj.bjc.6605437PubMedCentralPubMedCrossRef
179.
Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M: Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA. 2009, 106: 3925-3929. 10.1073/pnas.0900189106PubMedCentralPubMedCrossRef
180.
Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007, 110: 735-742. 10.1182/blood-2006-12-060947PubMedCentralPubMedCrossRef
181.
Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML: Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008, 455: 1205-1209. 10.1038/nature07284PubMedCentralPubMedCrossRef
182.
Adler JT, Cook M, Luo Y, Pitt SC, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H: Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther. 2009, 8: 914-920. 10.1158/1535-7163.MCT-08-0712PubMedCentralPubMedCrossRef
183.
Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008, 68: 6643-6651. 10.1158/0008-5472.CAN-08-0850PubMedCentralPubMedCrossRef
Metadata
Title
Glycogen synthase kinase 3 beta: can it be a target for oral cancer
Author
Rajakishore Mishra
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-144

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood

Research

Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion

Research

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors

Short communication

Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells

Research

PKCα expression is a marker for breast cancer aggressiveness

Research

The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits